BMS-986299

• Description:

  BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1) .

• UNSPSC:

  12352005

• Target:

  NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bms-986299.html

• Concentration:

  10mM

• Purity:

  99.96

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  O=C(C)N(CC)CC1=NC2=C(N1)C3=C(C=C(C4=NNC=C4)C=C3)N=C2N

• Molecular Formula:

  C18H19N7O

• Molecular Weight:

  349.39

• References & Citations:

  [1]Gary Glick, et al. Substituted imidazo-quinolines as nlrp3 modulators. WO2018152396A1.|[2]Gao G, et al., Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro. Front Pharmacol. 2022 Jul 5;13:906548.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  NLRP3

• CAS Number:

  [2242952-69-6]